Abstract 5093
Background
PDR (Pulsed Dose Rate) Brachytherapy is one of the treatments of choice for cervical cancer. Main side-effects are vaginal dryness, dyspareunia, pain, stenosis and sexual dysfunction that impacts on the patient’s well-being and on quality of life. To evaluate the efficacy of vaginal moisture to reduce dryness and pain associated with PDR Brachytherapy in cervical cancer patients treated at Catalan Institute of Oncology-Barcelona.
Methods
A quasi-experimental randomized study. From 2016 to 2018 all women were assessed by nurses 4 times: basal at discharge, 1st, 3rd and 6th month post-treatment. Experimental intervention with moisturizing versus standard care. Inclusion criteria; women diagnosed of cervical cancer receiving PDR. Probabilistic sampling of patients assigned 42 to control group CG and 47 to experimental group (EG). Variables: vaginal hydration, pain, age, ethnicity, comfort perceived, socio-demographic, tobacco, sexual relationship and couples. Instruments: LENT/SOMA to assess vaginal toxicity and visual numeric for pain.
Results
Of the 96 eligible, some excluded for relapse, or study failure. N = 89 women. Mean age: 52.78 + 12.8 (range 24-83) years old. Ethnicity; 63.8% white, Latina 3.1%, Arabic and Asiatic 0.8% each and gypsies 1.6%. Education; 3.1% illiteracy, primary 32.2%, secondary 25.2% and university 7.2%. Smokers 29.2%. For variable pain was 15-15-17-15 in CG and 20-17-15-13 in EG for consecutive points. Dyspareunia was present in 0-4-8-7 patients and 3-0-2-2 in EG. Dryness was 1-9-13-12 in CG and 6-1-8-10 in EG. Bleeding was 17-5-5-7 in CG and 16-10-0-6 in EG. Only significance differences on dryness variable. A total of 48.31% women avoid sexual intercourse, 22 (24.71%) in CG and 21 (23.59%). No significance differences.
Conclusions
An early vaginal moisturizing post-brachytherapy decreases the appearance of dyspareunia, allows start sexual relationships and improves the quality of life and sense of well-being. However some patients do not give the necessary importance to sexuality and it is something that they put aside during the treatment. Nursing education for patients at discharge helps to facilitate a healthy sexuality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract